Bionano Genomics (BNGO) vs Precipio (PRPO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precipio (PRPO) has outperformed Bionano Genomics (BNGO) over the past year, gaining 26.4% versus a loss of 26.3%. Over five years, PRPO leads with a -54.7% price change compared with -100.0% for BNGO. Precipio is the larger company by market cap ($41.4 million vs $16.9 million), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNGO | PRPO |
|---|---|---|
| Share price | $1.44 | $23.12 |
| Market cap | $16.90M | $41.39M |
| 1-day change | -1.71% | -0.30% |
| YTD return | -4.58% | +0.91% |
| 1-year return | -26.26% | +26.38% |
| 5-year return | -99.95% | -54.71% |
| Forward P/E | — | 59.28 |
| EPS (TTM) | $-3.02 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.23 | $33.63 |
| 52-week low | $1.00 | $16.40 |
| Distance from 52-week high | -35.65% | -31.25% |
| Analyst consensus | none | — |
| Avg. price target upside | +248.43% | — |
| Average volume | 921.59K | 127.60K |
| Shares outstanding | 11.78M | 1.79M |
| Employees | 95 | 61 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Precipio is about 2.4 times larger than Bionano Genomics by market value ($41.39M vs $16.90M).
- PRPO has outperformed BNGO by 52.6 percentage points over the past year.
About Bionano Genomics
BNGO stock →Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
Industrials · Biotechnology: Laboratory Analytical Instruments · 95 employees
About Precipio
PRPO stock →Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 61 employees
BNGO vs PRPO FAQ
Which is bigger, Bionano Genomics or Precipio?
Precipio (PRPO) is larger, with a market capitalization of $41.39M compared with $16.90M for Bionano Genomics (BNGO).
Which stock has performed better over the past year, BNGO or PRPO?
PRPO returned +26.38% over the past 12 months, compared with -26.26% for BNGO (price return, excluding dividends). Past performance does not predict future results.
Are Bionano Genomics and Precipio in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.